| For: | Yang WQ, Xue LL, Wang JL. Metabolic dysfunction-associated steatotic liver disease: Mechanisms, metabolic reprogramming, and therapeutic insights. World J Gastroenterol 2025; 31(26): 108814 [PMID: 40678711 DOI: 10.3748/wjg.v31.i26.108814] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i26/108814.htm |
| Number | Citing Articles |
| 1 |
Simin Riahy, Gholamreza Hamidian, Hasan Hadi Al-Ziyadi, Nader Hamedchaman. Hepatic LOX-1 Downregulation Is Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease Improvement in High-Fat Diet-Fed Rats: Protective Role of Aerobic <i>Exercise</i>. Hepatitis Monthly 2026; 26(1) doi: 10.5812/hepatmon-169226
|
| 2 |
Jiao Yu, Mengan Guo, Qiaoli Zhou, Lina Xue, Wenhua Wang, Xiao Wu, Yufeng Qin, Wei Gu, Guizhen Du. Hexafluoropropylene oxide trimer acid (HFPO-TA) exposure predisposes to MASLD through reprogramming hepatic epigenome and transcriptome. Ecotoxicology and Environmental Safety 2026; 312 doi: 10.1016/j.ecoenv.2026.119940
|
| 3 |
Debabrata Dash, Raj Kumar Koiri. Metabolic dysfunction associated steatotic liver disease as a disorder of hepatic bioenergetic timing. Medical Hypotheses 2026; 211 doi: 10.1016/j.mehy.2026.111970
|
| 4 |
Busong Wang, Yiping Tang, Na Li, Xuening Dai, Jing Wu, Bin Xue, Yuxin Chen, Jingzi Zhang, Lingdong Kong, Chaojun Li, Lei Fang. FBP1‐Mediated Compartmentalization of Glycolytic Enzyme Complexes Suppresses PKM2 Function to Ameliorate MASLD Progression. Advanced Science 2026; doi: 10.1002/advs.77875
|